HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $64 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Rhythm Pharmaceuticals, maintaining a price target of $64. This suggests confidence in the company's future performance.
October 25, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Rhythm Pharmaceuticals, maintaining a $64 price target. This indicates a positive outlook and confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $64 price target by HC Wainwright & Co. suggests strong confidence in Rhythm Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100